Sequent Scientific Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 14, 2023 at 05:56 pm IST
Share
Sequent Scientific Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 3,753.13 million compared to INR 3,580.47 million a year ago. Revenue was INR 3,781.76 million compared to INR 3,617.15 million a year ago. Net loss was INR 88.69 million compared to net income of INR 171.16 million a year ago. Basic loss per share from continuing operations was INR 0.36 compared to basic earnings per share from continuing operations of INR 0.69 a year ago. Diluted loss per share from continuing operations was INR 0.36 compared to diluted earnings per share from continuing operations of INR 0.68 a year ago.
For the nine months, sales was INR 10,542.41 million compared to INR 10,291.07 million a year ago. Revenue was INR 10,588.94 million compared to INR 10,361.82 million a year ago. Net loss was INR 275.85 million compared to net income of INR 322.89 million a year ago. Basic loss per share from continuing operations was INR 1.11 compared to basic earnings per share from continuing operations of INR 1.31 a year ago. Diluted loss per share from continuing operations was INR 1.11 compared to diluted earnings per share from continuing operations of INR 1.29 a year ago.
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.